3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hematologic Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Bone Marrow Failure Disorders
1
Interventions
Doxorubicin
15
pembrolizumab
12
Surgical Procedures, Operative
8
Cyclophosphamide
8
Blood Specimen Collection
8
Ifosfamide
7
Gemcitabine
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
atezolizumab
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
pazopanib
3
liposomal doxorubicin
3
fludarabine
3
cabozantinib
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled